Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 125

Similar articles for PubMed (Select 21145196)

1.

HIV neuropathy risk factors and symptom characterization in stavudine-exposed South Africans.

Wadley AL, Cherry CL, Price P, Kamerman PR.

J Pain Symptom Manage. 2011 Apr;41(4):700-6. doi: 10.1016/j.jpainsymman.2010.07.006. Epub 2010 Dec 8.

PMID:
21145196
2.

Age and height predict neuropathy risk in patients with HIV prescribed stavudine.

Cherry CL, Affandi JS, Imran D, Yunihastuti E, Smyth K, Vanar S, Kamarulzaman A, Price P.

Neurology. 2009 Jul 28;73(4):315-20. doi: 10.1212/WNL.0b013e3181af7a22.

PMID:
19636052
3.

HIV neuropathy in South Africans: frequency, characteristics, and risk factors.

Maritz J, Benatar M, Dave JA, Harrison TB, Badri M, Levitt NS, Heckmann JM.

Muscle Nerve. 2010 May;41(5):599-606. doi: 10.1002/mus.21535.

PMID:
20229576
4.

Peripheral neuropathy during stavudine-didanosine antiretroviral therapy.

Reliquet V, Mussini JM, Chennebault JM, Lafeuillade A, Raffi F.

HIV Med. 2001 Apr;2(2):92-6.

PMID:
11737385
5.

Tumour necrosis factor haplotypes associated with sensory neuropathy in Asian and Caucasian human immunodeficiency virus patients.

Chew CS, Cherry CL, Imran D, Yunihastuti E, Kamarulzaman A, Varna S, Ismail R, Phipps M, Aghafar Z, Gut I, Price P.

Tissue Antigens. 2011 Feb;77(2):126-30. doi: 10.1111/j.1399-0039.2010.01570.x. Epub 2010 Sep 30.

PMID:
20887379
6.

Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda.

van Griensven J, Zachariah R, Rasschaert F, Mugabo J, Atté EF, Reid T.

Trans R Soc Trop Med Hyg. 2010 Feb;104(2):148-53. doi: 10.1016/j.trstmh.2009.07.009. Epub 2009 Sep 3.

PMID:
19732926
7.
8.

Hepatitis C seropositivity is not a risk factor for sensory neuropathy among patients with HIV.

Cherry CL, Affandi JS, Brew BJ, Creighton J, Djauzi S, Hooker DJ, Imran D, Kamarulzaman A, Kamerman P, McArthur JC, Moore RD, Price P, Smyth K, Tan IL, Vanar S, Wadley A, Wesselingh SL, Yunihastuti E.

Neurology. 2010 May 11;74(19):1538-42. doi: 10.1212/WNL.0b013e3181dd436d.

9.

Stavudine-associated peripheral neuropathy in zidovudine-naïve patients: effect of stavudine exposure and antiretroviral experience.

Scarsella A, Coodley G, Shalit P, Anderson R, Fisher RL, Liao Q, Ross LL, Hernandez JE.

Adv Ther. 2002 Jan-Feb;19(1):1-8.

PMID:
12008857
10.

Once-daily administration of didanosine in combination with stavudine in antiretroviral-naive patients. The STADI Group.

Reynes J, Denisi R, Massip P, Izopet J, Pellegrin I, Segondy M.

J Acquir Immune Defic Syndr. 1999 Sep 1;22(1):103-5. No abstract available.

PMID:
10534154
11.

Effects of a reduced dose of stavudine on the incidence and severity of peripheral neuropathy in HIV-infected adults in South Africa.

Pahuja M, Grobler A, Glesby MJ, Karim F, Parker G, Gumede S, Naidoo K.

Antivir Ther. 2012;17(4):737-43. doi: 10.3851/IMP2087. Epub 2012 Mar 13.

12.

Increased incidence of peripheral neuropathy with co-administration of stavudine and isoniazid in HIV-infected individuals.

Breen RA, Lipman MC, Johnson MA.

AIDS. 2000 Mar 31;14(5):615. No abstract available.

PMID:
10780724
13.

Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm3.

Pollard RB, Peterson D, Hardy D, Pottage J, Murphy RL, Gathe J, Beall G, Rutkievicz V, Reynolds L, Cross AP, Dunkle LM.

J Acquir Immune Defic Syndr. 1999 Sep 1;22(1):39-48.

PMID:
10534145
14.

Excess peripheral neuropathy in patients treated with hydroxyurea plus didanosine and stavudine for HIV infection.

Cepeda JA, Wilks D.

AIDS. 2000 Feb 18;14(3):332-3. No abstract available.

PMID:
10716516
15.

Increased incidence of symptomatic peripheral neuropathy among adults receiving stavudine- versus zidovudine-based antiretroviral regimens in Kenya.

McGrath CJ, Njoroge J, John-Stewart GC, Kohler PK, Benki-Nugent SF, Thiga JW, Etyang A, Chung MH.

J Neurovirol. 2012 Jun;18(3):200-4. doi: 10.1007/s13365-012-0098-x. Epub 2012 Apr 17.

16.

Time for a change?

Little S, del Rio C.

AIDS Clin Care. 1998 Dec;10(12):92, 98.

PMID:
11366070
17.

Lactate concentrations distinguish between nucleoside neuropathy and HIV neuropathy.

Brew BJ, Tisch S, Law M.

AIDS. 2003 May 2;17(7):1094-6.

PMID:
12700465
18.

Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006.

Smyth K, Affandi JS, McArthur JC, Bowtell-Harris C, Mijch AM, Watson K, Costello K, Woolley IJ, Price P, Wesselingh SL, Cherry CL.

HIV Med. 2007 Sep;8(6):367-73.

PMID:
17661844
19.

Peripheral neuropathy in patients with HIV infection: consider dual pathology.

Miller RF, Bunting S, Sadiq ST, Manji H.

Sex Transm Infect. 2002 Dec;78(6):462-3.

20.

Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. Swiss HIV Cohort Study.

Rutschmann OT, Vernazza PL, Bucher HC, Opravil M, Ledergerber B, Telenti A, Malinverni R, Bernasconi E, Fagard C, Leduc D, Perrin L, Hirschel B.

AIDS. 2000 Sep 29;14(14):2145-51.

PMID:
11061656
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk